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Abstract
Background
Individuals with high intensity of Loa loa are at risk of developing serious adverse events
(SAEs) post treatment with ivermectin. These SAEs have remained unclear and a program-
matic impediment to the advancement of community directed treatment with ivermectin.
The pathogenesis of these SAEs following ivermectin has never been investigated experi-
mentally. The Loa/baboon (Papio anubis) model can be used to investigate the pathogene-
sis of Loa-associated encephalopathy following ivermectin treatment in humans.
Methods
12 baboons with microfilarial loads > 8,000mf/mL of blood were randomised into four
groups: Group 1 (control group receiving no drug), Group 2 receiving ivermectin (IVM)
alone, Group 3 receiving ivermectin plus aspirin (IVM + ASA), and Group 4 receiving iver-
mectin plus prednisone (IVM + PSE). Blood samples collected before treatment and at Day
5, 7 or 10 post treatment, were analysed for parasitological, hematological and biochemical
parameters using standard techniques. Clinical monitoring of animals for side effects took
place every 6 hours post treatment until autopsy. At autopsy free fluids and a large number
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of standard organs were collected, examined and tissues fixed in 10% buffered formalin and
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Results
Mf counts dropped significantly (p<0.05) in all animals following ivermectin treatment with
reductions as high as (89.9%) recorded; while no significant drop was observed in the con-
trol animals. Apart from haemoglobin (Hb) levels which recorded a significant (p = 0.028)
drop post treatment, all other haematological and biochemical parameters did not show any
significant changes (p>0.05). All animals became withdrawn 48 hours after IVM administra-
tion. All treated animals recorded clinical manifestations including rashes, itching, diarrhoea,
conjunctival haemorrhages, lymph node enlargement, pinkish ears, swollen face and rest-
lessness; one animal died 5 hours after IVM administration. Macroscopic changes in post-
mortem tissues observed comprised haemorrhages in the brain, lungs, heart, which seen
in all groups given ivermectin but not in the untreated animals. Microscopically, the major
cellular changes seen, which were present in all the ivermectin treated animals included
microfilariae in varying degrees of degeneration in small vessels. These were frequently
associated with fibrin deposition, endothelial changes including damage to the integrity of
the blood vessel and the presence of extravascular erythrocytes (haemorrhages). There
was an increased presence of eosinophils and other chronic inflammatory types in certain
tissues and organs, often in large numbers and associated with microfilarial destruction.
Highly vascularized organs like the brain, heart, lungs and kidneys were observed to have
more microfilariae in tissue sections. The number of mf seen in the brain and kidneys of ani-
mals administered IVM alone tripled that of control animals. Co-administration of IVM + PSE
caused a greater increase in mf in the brain and kidneys while the reverse was noticed with
the co-administration of IVM + ASA.
Conclusions
The treatment of Loa hyper-microfilaraemic individuals with ivermectin produces a clinical
spectrum that parallels that seen in Loa hyper-microfilaraemic humans treated with ivermec-
tin. The utilization of this experimental model can contribute to the improved management of
the adverse responses in humans.
Author summary
The pathogenesis of the serious adverse reactions that occur in patients carrying high
loads (usually > 30,000mf/mL) of circulating Loa loa parasites and treated with ivermec-
tin has to date not been clearly defined at the tissue level. These reactions, which can result
in the death of many of those affects and cause permanent mental damage in others,
inflicts considerable disruption to the important mass treatment programs to control and
eliminate filariae where ivermectin is used. The recently described baboon model of
hyper-microfilariaemia has been used here to study the pathological changes occurring
after ivermectin treatment; the clinico-pathological presentation following treatment in
baboons appears to be closely related to those seen in humans. The tissue changes seen
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suggest that the primary pathological event following ivermectin treatment is a vasculopa-
thy associated with intra-vascular microfilarial destruction within smaller blood vessels
that damages them and leads to changes in the tissues supplied by these vessels. The effects
of cortisone and aspirin on these changes are also addressed in this study.
Introduction
Loa loa is a parasitic filarial nematode of humans, restricted to the rainforest and forest fringes
of West and Central Africa [1], causing the relatively well-tolerated disease-loiasis. Loiasis has
two very characteristic clinical features: Calabar swellings, corresponding to an angioedema of
allergic nature [2] and the passage of an adult worm under the conjunctiva (eyeworm). Other
complications, though rare, include nephropathy [3], cardiomyopathy [4], retinopathy [5],
arthritis [6], lymphangitis [7], peripheral neuropathy [8] and encephalopathy [9].
Loiasis is an infection of public health importance, essentially not because of its own clinical
manifestations, but because it is associated with serious adverse events (SAEs) following the
administration of ivermectin. These SAEs have a negative impact on the ongoing control of
onchocerciasis and lymphatic filariasis with ivermectin distribution in areas of co-endemicity
with Loa. The occurrence of Loa-associated SAEs with programs for these two major filariae
(onchocerciasis and lymphatic filariasis) in L. loa endemic areas has been increasingly reported
over the past decade. Clinical problems seen include severely disabling and potentially fatal,
encephalopathy as well as other permanent clinical changes. Current observations have indi-
cated that the risk of developing marked or serious reactions is significantly higher when the L.
loa loads exceeds 8,000mf/mL; the severity of these reactions becomes more common in patients
with the risk of these happening and being severe much higher in patients with> 30,000 mf/
mL, with the risk of problems being very high with loads above with> 50,000mf/mL [10–13].
Although the epidemiological mapping and clinical description of these Loa-associated
SAEs is now well known, the pathogenesis and the optimal approaches to treatment still
remain obscure. An increase in the presence of L. loa in the brain tissue has been proposed as
an important feature of the condition, and a central role for vascular pathology in the adverse
reaction also proposed [14, 15]. Understanding the mechanism of pathogenesis of the post-
ivermectin events in these heavily infected individuals is an important step towards the devel-
opment of better treatments and responses to this unfortunate pathology. The lack of data
from human cases and especially the lack of autopsy material have hindered the progress in
the treatment and prevention of this condition. The previous lack of a relevant experimental
model also contributed to the lack of solid information on these adverse reactions and delay in
developing suitable clinical treatment protocols. A better understanding of the pathogenesis of
this post-treatment condition is urgently needed.
After several consultation meetings held by the Scientific working Group on SAE in L. loa
endemic countries, [16], it was strongly recommended that a non-human primate (NHP) ani-
mal model of Loa encephalopathy be developed. Non-human primates (NHP) are therefore
considered the best models for the much needed investigation in human loiasis, especially as
suitable in vitro models for loiasis have not yet been developed, and indeed such artificial mod-
els are not easily extrapolated to humans [17–19]. Although the drill is an excellent experimen-
tal host, there are ethical concerns with using this protected animal for research, and it is no
longer used in biomedicine. The use of Patas monkeys also is limited as the parasite behaves
differently from the same way that it does in the more human-like drill [20].
As recently described, the baboon (P. anubis) is a potentially useful model for studying the
mechanisms behind the SAEs that develop in L. loa infected people as the parasite in this
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animal behaves essentially in the same way as it does in the drill. The use of baboons in bio-
medical research is accepted by the International Union for Conservation of Nature (IUCN)
[21] and so Wanji et al developed a hyper-microfilaraemic Loa/baboon (Papio anubis) experi-
mental model and characterized it parasitologically, haematologically and biochemically [22].
In this model microfilariaemia increases steadily in all infected animals and reaches a peak at
18 months post infection (MPI); by 10 MPI >70% of animals have mf > 8,000 mf/mL, at 18
MPI >70% of animals have mf>30,000mf/mL and 50% of animals have mf>50,000mf/mL.
In this study, the three most significant alterations seen were: increased eosinophil, creatinine
and gamma-GT levels. An intriguing question that now emerges is whether these specific alter-
ations bear any role in the development of the post ivermectin SAEs. It also remains to be dem-
onstrated whether if these Loa hyper-microfilaraemic baboons are treated with ivermectin-IVM
(i) There will be a drastic drop in microfilariae load? (ii) Treatment will lead to serious clinical
manifestations? (iii) There will be changes in blood chemistry and haematological parameters?
(iv) Microfilariae will be seen in the different tissues and their distribution? (v) Which lesions
will be seen and what are their characteristics (vi) and if the co-administration of ivermectin
with either aspirin or prednisone will affect points i-v above. Therefore, this present study was
carried out to treat Loa hyper-microfilaraemic animals such as to validate the model as a surro-
gate for the human condition, and to provide answers to the questions above.
Materials and methods
Animals
The acquisition, care and ethical concerns on the use of these animals have already been
described in the preceding paper [22]. The animals for this study were gotten from the 15
baboons that had been characterised parasitologically, biochemically and haematologically in
the preceding paper [22].
Eligibility criteria and randomization into trial groups
Baboons to be included in the trials were chosen amongst the experimentally infected 15
animals. The inclusion criterion for animals to enter the drug treatment phase was a micro-
scopically confirmed microfilariaemia of>8,000mf/mL whilst the exclusion criterion was a
microfilariaemia of<8,000mf/mL. Ultimately, 12 infected splenectomised baboons were
included in this phase of the study. The 12 baboons were randomised into 4 arms, with each
treated group consisting of three animals. Eligible baboons were randomly assigned to the dif-
ferent treatment arms using a computer generated randomisation list. The randomisation was
performed by a statistician not otherwise engaged in the study. The initial treatment allocation
and the number of days animals were to be monitored were concealed but the subsequent
administration of medication(s) was open label. Animals were placed into three different
experiments based on the number of days animals were to be monitored; animals in experi-
ment 1 were monitored for 5 days, those in experiment 2 for 7 days and those in experiment 3
for 10 days. After the randomization into treatment groups, the study was designed according
to the flow diagram shown in Fig 1.
Collection of pre-treatment and post-treatment data
Ten mL venous blood samples were collected under anesthesia (0.1 mL ketamine) and aseptic
conditions from the femoral vein of each animal for parasitological (L. loa), haematological
and biochemical analyses on Day 0 before treatment and on Days 5, 7 or 10 post treatment
depending on the animals experimental group by a licensed veterinarian. Calibrated thick
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blood smears were prepared by spreading a 50 μL venous blood sample from a 75 μL non-
heparinised capillary tube, onto a clean slide over an area of 1.5 cm x 2.5 cm for both the pre-
treatment and post treatment samples.
The haematological parameters assessed were haemoglobin (Hb), red blood cell count
(RBC), total white blood cell count (WBC) and white cell differential count in which neutro-
phils, eosinophils, basophils, monocytes and lymphocyte counts were measured. These analy-
ses were performed on the pre- and post-treatment samples. The biochemical parameters
quantified were grouped into the liver enzymes consisting of serum glutamate-pyruvate trans-
aminase (SGPT), serum glutamate-oxaloacetate transaminase (SGOT) and serum γ-glutamyl
transferase (γ-GT); blood biochemistry compounds comprising of creatinine and glucose; and
blood elemental biochemistry comprising of calcium and potassium. The biochemical parame-
ters were quantified using spectrophotometric kits obtained from HUMAN (www.human.de,
Germany) as per the manufacturer’s instructions. The parasitological, haematological and bio-
chemical analyses were performed on the pre- and post-treatment samples as described previ-
ously in Wanji et al., [22].
Administration of drugs
The ivermectin used for this study was provided by the Mectizan Donation Program (MDP),
and the aspirin (ASA) and prednisone (PSE) used in the study acquired commercially from
Fig 1. The study design.
https://doi.org/10.1371/journal.pntd.0005576.g001
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Bayer and Ranbaxy laboratories Ltd., respectively. The animals were administered drugs via
the oral route by a licensed veterinarian. Group 1 animal served as controls and received no
drugs. Group 2 animals (IVM) received ivermectin alone. Group 3 animals (IVM+ASA)
received IVM and 3 days after IVM administration, they received aspirin (1 tablet of 500mg 2
times a day) for two days; Group 4 animals (IVM+PSE) received IVM and 3 days after IVM
administration, they received PSE (4 tablets of 5mg 2 times a day) for two days. The standard
doses of ivermectin (150μg/kg of body weight), 500mg of ASA and 5mg of PSE were used for
this study.
Clinical monitoring
Clinical surveillance was carried out for up to 10 days. Following treatment, animals were
closely monitored every day on a six hourly basis. Animals were assessed for general agility,
meningeal signs, discharges, papillary reflex, diarrhea, weakness, conjunctival haemorrhage,
dyspnea, itching (excoriations), muscle aches, restlessness, gland pain and gland tenderness,
presence of rashes, pinkish ears, joint pain and swollen face. The agility and playing habits of
the monkeys were assessed by the animal caretaker who was familiar with the normal behav-
iour of these baboons. Rashes were considered absent when none were found on the body of
the animal, mild when < 3%, moderate when 3–10%, severe when 11–50% and unbearable
when> 50%, of the body surface was affected. Itching was considered absent when no excoria-
tions were found on the body of the animal, to be mild when < 3% of the body surface had
excoriations, moderate when 3–10%, severe when 11–50%, and unbearable when > 50% of the
body surface had excoriations. Gland pain/tenderness was assessed by palpating collections of
lymph nodes in the neck, axillae and inguinal regions, and were considered as absent if no
enlarged nodes were found; mild when the enlarged nodes were localized i.e. 1–2 enlarged
nodes were found in one body area; moderate if 3–5 enlarged nodes were found in one body
area; severe when 3–7 enlarged lymph nodes were generalized i.e. found in 2 or more body
areas and unbearable when > 10 enlarged lymph nodes were generalized. Restlessness was
assessed by counting the number of times the animals could not sit still; restlessness was con-
sidered absent when the animals sat still all the time, mild when it could not be still for less
than 5 times, moderate when it could not be still for about 8–15 times, severe when it could
not be still for 15 times and unbearable when the animal could not remain sitting still. Vital
signs like rectal temperature, pulse rate (PR) and respiratory rate (RR) were also recorded.
Animals in Experiment 1 were monitored every 6 hours for 5 days for a period of 120 mins,
those in Experiment 2 every 6 hours for 7 days for a period of 168 mins while those in Experi-
ment 3 were monitored every 6 hours for 10 days for 240 mins before autopsy.
Pathology
The animals were euthanized by the administration of 10 mL of 5mg ketamine (Imalgene,
Merial, France) and autopsies performed immediately. Gross organ and pathophysiologic
abnormalities were observed during necropsy. Organs observed were the skin, brain, liver,
lungs, diaphragm, pancreas, kidneys, heart, digestive tract and lymph nodes. These organs
were collected and fixed in 10% formol (3% formaldehyde). Following paraffin embedding
and sectioning (5 μm) the tissues were stained with a range of histochemical (haematoxylin-
eosin) and immunochemical reagents (REF-350 was used to identify thrombi and UCH-ICC
was used to identify the presence of macrophage cell lines) using standard immunocytochemi-
cal procedures from the Department of Pathology/Histology of the Michigan State University,
Michigan, U.S.A.
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Microscopic examination of stained tissue sections
Slides with stained tissues of the brain, liver, lungs, skin, diaphragm, pancreas, kidneys, heart,
digestive tract and lymph nodes were used to estimate Loa mf numbers and also analysed for
pathologic changes. Ruled out papers of 50mm2 and 12.5mm2 were used to carve out areas on
the prepared slides for organs with large surface areas (e. g. brain, kidney, lungs, etc.) and
those with small surface areas (e. g. skin, lymph nodes, pancreas, etc.), respectively. The slides
were rapidly focused at x10 to trace out the borders of the marked area and to check for Loa
mf, after which the x40 objective was used to confirm the presence of Loa parasites and esti-
mate the Loa mf numbers. After the counts had been made, the distribution of mf/25mm2 in
all organs was calculated. The histopathological tissues were observed and interpreted by two
trained histopathologists (CDM, DA).
Data analysis
Normal ranges for various vital signs (temperature, respiratory rate (RR) and pulse rate (PR)
in baboons were gotten from the Association of Primate Veterinarians Primate Formulary
(1999) for baboons housed individually in large custom cages. The data were entered into Epi-
Info version 3.5.3 (C.D.C. Atlanta, GA, U.S.A.) and analysed using the Software Package SPSS
version 20. Graphs were drawn using the Graph Pad Prism version 5 for windows, Graphpad
Software, San Diego California, U.S.A. Descriptive statistical analyses were performed to com-
pute the mean, median and standard deviations of Loa microfilarial counts, haematological
and biochemical parameters in the animals pre- and post-treatment. The percentage reduction
of peripheral mf following treatment in the different baboons was calculated using the formula
below:
% reduction of mf ¼
mf before treatment   mf after treatment x 100
mf before treatment
The Pearson’s Chi square test was used to test for significant differences in percentage
reductions of mf between groups. The Wilcoxon signed rank test was used to test for any sig-
nificant differences in mf counts, haematological and biochemical parameters before and after
treatment.
All clinical manifestations observed were described based on scores defined as: 0 = normal/
absent/no alteration, 5 = mild, 10 = moderate, 15 = severe and 20 = unbearable. The Kruskal
and Wallis test was used to test for significant differences in vital signs. Bar charts were used to
represent the mean scores of clinical signs in the different treatment groups. The distribution
of mf/25mm2 in the different organs for animals in the different treatment arms were repre-
sented using bar charts; the Kruskal and Wallis test was used to test for significant differences
in the distribution of tissue mfs. A description of the different lesions observed at the gross and
histological levels were done. The mf found in the different tissues of Bab 08 was considered
under the category of IVM only, because it took only this drug and died 5 hours after. All tests
were performed at 5% significance level.
Results
Reduction of peripheral mf counts after ivermectin treatment
The pre-treatment Loa microfilaraemia load ranged from 19,800–124,700 mf/mL; median
39,500 mf/mL of blood and the post-treatment microfilarial load ranged from 160–34,660mf/
mL; median 12,900 mf/mL of blood.
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The untreated animals showed an overall percentage fluctuation of 3.4% over the 10 days
period monitored. After 5 days of monitoring, these animals showed a reduction of 22.6%
whereas the animals monitored for 7 and 10 days showed increases in the mf numbers of 8.8%
and 3.5%, respectively from day 0 (Fig 2A).
For all animals administered IVM (IVM alone, IVM+ASA and IVM+PSE), the overall
reduction in mf load after ivermectin treatment was 75.7%. Animals monitored for 7 days
Fig 2. Changes in Loa mf loads a different time points. a. Untreated animals. b. Following ivermectin
treatment.
https://doi.org/10.1371/journal.pntd.0005576.g002
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recorded the highest (96.9%) reduction in mf loads following treatment whereas those moni-
tored for 5 days recorded the lowest (59.5%) of the reductions seen in mf loads with treated
animals (Fig 2). There was a significant difference (p = 0.02) in percentage reduction in ani-
mals treated at different time points. For each treated animal, there was a significant drop in
microfilaraemia p<0.05, Table 1. Bab 05 (with an initial Loa mf load of 10,080 mf/mL)
recorded the highest (98.4%) reduction in mf numbers while Bab 02 (with an initial Loa mf
load of 79,660 mf/mL) recorded the lowest (61.8%) reduction in mf numbers after treatment
with IVM. The percentage reduction in individual animals treated with IVM is shown in
Table 1.
With respect to treatment groups, the highest percentage reduction (89.9%) in peripheral
mf loads was recorded in animals that were administered IVM alone (Fig 3). There was a sig-
nificant difference (p = 0.03) in percentage reduction in animals in the different treatment
arms administered ivermectin.
Changes in haematological parameters following treatment
Amongst all the haematological parameters monitored there was a significant difference
between the pre- and post-haematological parameters when looked globally (p = 0.028). Hae-
moglobin values before treatment ranged from 12–16 g/ dL; median 14.7 g/dL while the post
treatment values ranged from 12–16 g/dL; median 12.8 g/dL. However, the Hb values pre- and
post-treatment remained the same (12g/dL) in animals which received IVM + PSE while for
animals that received IVM alone and IVM + ASA reduced post treatment by 3 g/dL and 1
g/dL, respectively.
However, in untreated animals increases were noticed in the RBC numbers and decreases
noticed in the WBC, neutrophil, mononuclear numbers before and after treatment, significant
differences were not noticed in the values for these parameters pre and post treatment between
the different treatment groups, (p>0.05) (S1 Table).
Although significant differences were not recorded (p>0.05) between the different treat-
ment groups, IVM administered alone caused increases in the values pre and post treatment
for WBC, eosinophils and mononuclear lymphocytes while a decrease in values pre and post
treatment was noticed in neutrophil numbers (S1 Table).
Table 1. Blood peripheral mf loads before and after different treatments.
Code Drug Administered Exp. Group No. Days Monitored Mf load BF Mf load AF Percentage
Reduction (%)
Z (Wilcoxon Signed Rank
Test)
P-value
Bab04 None 3 10 21580 25160 -16.4 — —
Bab10 None 1 5 19800 18820 4.9 — —
Bab11 None 2 7 31560 26460 16.2 — —
Bab05 IVM 2 7 10080 160 98.4 -5.385 0.002
Bab07 IVM 1 5 92780 10940 88.2 -3.464 0.001
Bab12 IVM 3 10 35760 6000 83.2 -4.796 0.004
Bab08* IVM 1 ——— 124700 —— ——— ——— ———
Bab01 IVM+ ASA 3 10 36400 12900 64.6 -6.164 0.001
Bab06 IVM+ ASA 2 7 42600 1860 95.6 -5.292 0.002
Bab09 IVM+ ASA 1 5 101140 34660 65.7 -3.742 0.003
Bab02 IVM + PSE 3 10 79660 30460 61.8 -6.164 0.002
Bab03 IVM + PSE 2 7 51480 3220 93.7 -5.385 0.003
*Animal died 5 hours after ivermectin treatment; BF = before treatment, AF = after treatment
https://doi.org/10.1371/journal.pntd.0005576.t001
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IVM +ASA co-administration caused increases in the values pre and post treatment for
neutrophils and decreases in RBC, WBC, eosinophils, mononuclear lymphocytes, although no
significant differences (p>0.05) were recorded in these values between the different treatment
groups (S1 Table).
IVM + PSE co-administration caused increases in the values pre and post treatment for
RBC and decreases in WBC, neutrophils eosinophils and mononuclear lymphocytes, although
no significant differences (p>0.05) were recorded in these values between the different treat-
ment groups (S1 Table).
Changes in biochemical parameters following treatment
The different biochemical parameters monitored did not show any significant changes in val-
ues pre and post treatment (p>0.05). The changes in all biochemical parameters before and
after treatment are shown in S2 Table.
In untreated animals though increases were noticed in the SGPT, SGOT, γ-GT, creatinine and
glucose levels numbers while decreases were noticed in the calcium and potassium numbers
before and after treatment, significant differences were not noticed in the values for these parame-
ters pre and post treatment, between the different treatment groups (p>0.05) (S2 Table).
Although significant differences were not recorded (p>0.05) between the different treat-
ment groups, IVM administered alone caused increases in the values pre and post treatment
for SGOT, glucose and calcium, while decreases in values pre and post treatment were noticed
in SGPT, γ-GT, creatinine and potassium (S2 Table).
IVM +ASA co-administration caused increases in the values pre and post treatment for
γ-GT, no changes in calcium levels and decreases in SGPT, SGOT, creatinine, glucose and
Fig 3. Changes in Loa mf loads with different treatment regimes. : ivermectin alone (IVM), ivermectin and aspirin (IVM
+ASA), and ivermectin and prednisone (IVM+PSE).
https://doi.org/10.1371/journal.pntd.0005576.g003
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potassium although no significant differences (p>0.05) were recorded in these values between
the different treatment groups (S2 Table).
IVM + PSE co-administration caused increases in SGPT, SGOT, γ-GT and glucose levels
and decreases in creatinine, calcium and potassium levels although no significant differences
(p>0.05) were recorded in these values between the different treatment groups (S2 Table).
Clinical manifestations observed in baboons
In all animals administered IVM at a standard dose of 150μg/kg on Day 0, they did not show
any clinical manifestations, however, Bab 08 (with an initial Loa mf load of 124,700mf/mL)
became unbearably restless, lost appetite and died 5 hours after treatment. On the second day
of observation post treatment, the following clinical manifestations being observed: an increase
in the observed temperature and respiratory and pulse rates. The temperature increased to
between 35–40.4˚C with a mean of 38.18±0.7752˚C (normal range: 37.56–39.17˚C) and respi-
ratory rates increased to 49-117/min with a mean of 85.25±13.91 breaths per minute (normal
range: 30–70 breaths per minute). The pulse rates ranged from 58–141 beats per minute with a
mean of 98.78±18.64 beats per minute (normal range: 120–180 beats per minute). A significant
difference (p = 0.045) was recorded in body temperature day 1 post treatment in the different
treatment groups while no significant differences (p>0.05) were recorded in the other vital
signs between animals in the different treatment groups, (Fig 4A–4C). The animals became
withdrawn 48 hours after IVM treatment (Fig 5).
Other clinical manifestations observed on this day were body rashes and itches (Fig 6A),
gland pain and gland tenderness, pinkish ears, swollen face, conjunctival haemorrhages, loss of
appetite, muscle ache, slight discharge form the eyes and nostrils and diarrhea. The mean
scores for rashes and itching observed in the various groups are shown in Fig 6B. Untreated
animals did not show any clinical alterations. On the third day after the administration of ASA
(1 tablet of 500mg 2 times a day for two days), the observed rashes and itches became absent or
mild in the animals in this treatment arm whereas after the administration of PSE (20mg 2
times a day for two days), the observed rashes and itches remained moderate.
Gross pathological findings
The macroscopic changes seen included changes that were primarily those of a vasculo-patho-
logic nature (e.g. haemorrhages, hyperaemia/injection, pleural effusions, etc.). Petechial haem-
orrhages were seen in the CNS, the lungs, the conjunctiva, the cardiac tissues, the peritoneum
and the omentum. Adult worms were present in the deep subcutaneous tissues as well as
the development of pleural effusions and enlarged and haemorrhagic lymph nodes, the skin
showed excoriations and pachydermia on the limbs. These changes were seen in all groups
given ivermectin, occurring at various levels, except in the untreated group (which showed
none of these changes). The majority (11/12) of baboons, all whom had been splenectomised
as part of inducing the infection with L. loa, were seen to have regrown “new splenic tissue”.
Most of these new tissues were variable in shape, located in the supra-renal area on the left or
at least within 10 centimeters of this area; in two animals there were two independent such
new organs in this anatomical location. These new tissues were most usually round ball-like
and on sectioning were dark red in colour with a distinct fibrous capsule with some visible tra-
beculae. The different pathological changes seen are shown in Fig 7A–7F.
Distribution of tissue microfilariae
Microfilariae were visible histologically in all animals. The brain and kidneys carried high
numbers of mf in all treatment groups whereas lower numbers of mf were present in organs
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Fig 4. Variations in clinical presentations after ivermectin treatment (A = temperature; B = respiratory rate;
C = pulse rate).
https://doi.org/10.1371/journal.pntd.0005576.g004
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such as the diaphragm, pancreas and intestine in all other treatment groups except in the
untreated infected group which recorded no mf in the diaphragm and pancreas. No significant
differences (p>0.05) were detected in the distribution of mf within the different organ tissues
between any of the treatment groups including the kidneys (p = 0.794), except in the brain tis-
sues, which had a significant more mf (p = 0.04) in animals from different treatment groups.
In untreated animals, mf was found in the tissues of all organs observed except in the dia-
phragm and pancreas. The highest numbers of mf counted in all observed tissues were in the
brain (4.2 mf/25 mm2 and kidneys (5.4 mf/25 mm2) of these animals. The distribution of mf in
the tissues of animals that served as controls can be seen in Fig 8. In animals treated with IVM
alone, mf were seen in all the observed tissues. In these animals, the mf increased greatly in
most of the tissues. In the brain the increase to 13.8 mf/25 mm2 was 3 times; in the kidneys the
decrease to 2 mf/25 mm2 in animals administered IVM alone was 3 times lower than that of
animals infected but remained untreated and in the lymph nodes the increase to 4 mf/25 mm2
was 4 times-that of control animals. The distribution of mf in tissues from the different organs
of animals that received IVM, can be seen in Fig 8.
Fig 5. The typical behavioral response after treatment: Depression and reluctance to participate in
normal activities.
https://doi.org/10.1371/journal.pntd.0005576.g005
Post-ivermectin changes in Loa hyper-microfilariaemic baboons
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005576 July 7, 2017 13 / 25
In animals administered aspirin after ivermectin treatment, mf were also seen in the
observed tissues. In these animals it was noticed that the mf seen in the tissues decreased
greatly after ASA was administered. In the brain the decrease to 2.8 mf/25 mm2) was 5 times;
kidneys the decrease to 8 mf/25 mm2) was 2 times; in the liver the decrease to 2.8 mf/25 mm2)
was 2 times; in the lymph node the decrease to 1.8 mf/25 mm2 was 3 times -that of animals
administered IVM alone. The distribution of mf in tissues from the different organs of animals
that received IVM + ASA, can be seen in Fig 8.
Microfilariae were equally observed in the tissues of animals administered prednisone after
IVM treatment. Here it was noticed that mf numbers increased greatly in the brain tissues. In
the brain the increase in mf to 17.4 mf/25 mm2 was 1.3 times that of animals administered
IVM alone. In the kidneys, liver and lungs decreases to 10 mf/25 mm2, 3.8 mf/25 mm2 and 2.8
mf/25 mm2, respectively, were noticed which were 0.9, 1.5 and 0.6 times, respectively as com-
pared to those of animals which were administered IVM alone. The distribution of mf in tis-
sues from the different organs of animals that received IVM, can be seen in Fig 9B.
Lesions in organs of baboons following treatment with ivermectin and
other drugs
The major cellular changes seen, and which were present in all the ivermectin treated animals,
were:
1. The presence of microfilariae of varying degrees of degeneration in small vessels, these
parasites were frequently associated with either fibrin deposition, endothelial alteration
(cellular swelling) including damage to the integrity of the blood vessel and the presence of
extravascular erythrocytes (haemorrhage).
Fig 6. Dermatological responses in baboons after treatment. Score for rashes and pruritus in baboons following ivermectin
treatment (Ranges used = 0: Normal/Absent/no alteration, 1–5: Mild, 6–10: Moderate, 11–15: Severe and 16–20: Unbearable).
https://doi.org/10.1371/journal.pntd.0005576.g006
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2. The increased presence of eosinophil leucocytes and other chronic inflammatory types in
certain tissues and organs, sometimes in large numbers. c. Local evidence of microfilarial
death, i.e. degenerating microfilariae.
The lesions found in untreated animals and in the first 72 hours after treatment with
ivermectin included eosinophilic accumulation in the tissues, accumulation of mf in the lym-
phoid tissues, fibrin deposition on the walls of cerebral blood vessels and mf degeneration and
eosinophilic accumulation/degranulation in a lymph node. These changes can be seen in Fig
10A–10F.
After 72 hr. following treatment, the observed lesions included blocked CNS vessels
comprised of eosinophils, fibrin, macrophages and parasite debris, blocked CNS vessels
with associated damage (vacuolation of the parenchyma), intact microfilariae caught in a
cellular intravascular mass in the CNS, degenerating mf in blood capillaries of the CNS
and surrounded by fibrin, and an area of vascular and parenchymal damage in the CNS
Fig 7. Macroscopic changes following ivermectin treatment. A. Petechial haemorrhages in the central
nervous system, B. Cardiac muscle section showing petechial haemorrhage, C. Petechial haemorrhages in
the lungs, D. Haemorrhagic lymph nodes in the omentum, E. Adult worm lesion present in the deep
subcutaneous tissues, and F. Newly formed splenic tissues approximately 18 months after splenectomy.
https://doi.org/10.1371/journal.pntd.0005576.g007
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predominately filled with macrophages and eosinophils. The different lesions seen more than
72 hours post treatment with ivermectin can be seen in Fig 10A–10F. The presence and extent
of histo-pathological changes seen in the different organs of the various treatment groups can
be seen in Table 2. The distribution of different lesions seen in the different tissues indicate
that they were mild in untreated animals while in animals administered ivermectin alone,
these lesions were moderate; the distribution of these lesions between treatment groups can be
seen in Table 3.
Discussion
In this report the clinical spectrum and pathology related to the treatment of hypermicrofilar-
aemic Loa infected baboons with ivermectin is presented for the first time. After treatment
with ivermectin, microfilaraemia decreased significantly in all treated animals with up to
98.4% reduction in one animal (Bab 05). This finding confirms the findings of earlier authors
who had shown ivermectin to have a marked microfilaricidal effect on L. Loa. A study by
Kamgno et al. [23] demonstrated that one month after a single dose with ivermectin, microfi-
larial loads fall to<20% of their initial values and this suppression of microfilaraemia can per-
sist for at least a year [24]. The reduction of microfilariae numbers in peripheral blood could
probably be due to the fact that ivermectin treatment induces the Loa microfilariae to flee
from the blood circulation into other body fluids such as the pleural and peritoneal fluids as a
result of vascular breaking or due to the death of these mfs.
Fig 8. Distribution of L. loa mf in the tissues of different organs in the four experimental groups: Control animals, animals
given ivermectin alone, animals given ivermectin and aspirin animals, and animals given ivermectin and prednisone.
https://doi.org/10.1371/journal.pntd.0005576.g008
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The drastic killing of circulatory mf could lead to the blockage of blood vessels in the differ-
ent tissues and organs. When this happens, an inflammatory reaction sets in activating the
fibrin pathway whereby fibrin clots are deposited in the tissues. The release of inflammatory
cytokines such as interleukin (IL)-1, IL-6, IL-17 and tumor necrosis factor alpha (TNF-α)
which have been incriminated as being part of pathological signal cascades in brain diseases
[25] could have been released in these animals, although these cytokines were not measured.
The formation of fibrin clots could result in the blockage of blood vessels in the different tis-
sues and organs causing tissue anoxia and finally death.
It is not clear as to the significant changes between the pre and post treatment haemoglobin
levels. However, no animals were found to be clinically anaemic, and as the animals were fed
Fig 9. Microscopic lesions present in the untreated and in the first 72 hours after treatment. A.
Microfilariae in dermal vessels. B. Eosinophil accumulation in the tissues, a typical response in the first 24
hours, C. Blood vessel free of mf- many normal vessels can also be seen free of mf in this phase, D.
Accumulation of mf in the lymphoid tissues, an event that is common within the first 2–3 days, E. Fibrin
deposition (red) on the walls of a cerebral vessel. F. Area of mf degeneration and eosinophil accumulation/
degranulation in a lymph node.
https://doi.org/10.1371/journal.pntd.0005576.g009
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on a rich protein-diet it is likely that this variation in parameter was not a major characteristic
of ivermectin’s effect on haemoglobin. In all treated animals, there was an increase in the total
white blood cell counts, eosinophils, and neutrophils. The increase in WBC counts is similar
to what Ducorps et al. found out in their study [10]. This increase is probably due to an
enhancement in the production of many more leukocytes to reduce the severity of Mazzotti
reaction and to fight the infection in general. The increase in eosinophils in this study is similar
Fig 10. Microscopic lesions present in the treated animals more than 72 hours after treatment. A. Adult
L. loa worm in connective tissue beneath the skin. B. Blocked CNS vessel comprised of eosinophils, fibrin,
macrophages and parasite debris. C. Blocked CNS vessels with associated damage (vacuolation of the
parenchyma). D. Intact microfilariae caught in a cellular intravascular mass in the CNS, E. A degenerating mf
in a capillary of the CNS and surrounded by fibrin. F. Area of vascular and parenchymal damage in the CNS
predominately filled with macrophages and eosinophils.
https://doi.org/10.1371/journal.pntd.0005576.g010
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to what Martin-Prevel et al. [26] noticed where treatment with ivermectin causes an increase
in eosinophils. The global changes in eosinophil counts recorded after treatment with ivermec-
tin in patients harbouring L. loa is similar to those observed in onchocerciasis patients after
treatment with ivermectin or DEC [27, 28]. This could probably be due to the preponderant
role of eosinophils in the development of the Mazzotti reaction whose severity is associated
with eosinophil sequestration and activation-degranulation [29, 30]. The increase in neutro-
phils observed is probably because these cells are the hallmarks of acute inflammation given
the fact that the migration and degranulation of eosinophil in the skin releases parasite specific
antigens during cell death that induces a pro-inflammatory response. The general increase
observed in SGPT, SGOT and γ-GT levels after ivermectin treatment could probably be due to
hepatocellular damage or obstruction in bile flow cholestasis [31, 32]. Generally, this drug has
not been associated with acute or chronic liver injury, although Veit et al., [33] realised that
Table 2. Presence and extent of histo-pathological changes in different organs (No. of animals per group).
Organ Infected untreated (1) Infected + ivermectin (3) Infected + ivermectin + aspirin (3) Infected + ivermectin +
prednisone (3)
CNS - + + +
Lungs - + + +
Lymph nodes - ++ + -
Liver + + + +
Kidney + ++ ++ ++
Skin + +++ +++
Spleen* ++ ++ ++ ++
Heart - ++ + +
Peritoneal cavity - + - _
Thoracic cavity - +++ + ++
Ocular tissues - + _ _
Intestine - + + +
* These are newly growing splenic structure.
Score: + = mild; ++ = moderate; +++ = severe
https://doi.org/10.1371/journal.pntd.0005576.t002
Table 3. Distribution of lesions between the different treatment groups (No. animals per group).
Pathological change Infected untreated
(1)
Infected + ivermectin
(3)
Infected + ivermectin
+ aspirin (3)
Infected + ivermectin
+ prednisone (3)
Intravascular lesions with mf - ++ + ++
Microfilarial destruction + ++ ++ ++
Micro-haemorrhages - + + +
Macro-haemorrhages - + + +
Eosinophil infiltration to lymph
nodes
- ++ (+) (+)
Eosinophil infiltration to other
tissues
- ++ + ++
Macrophage responses to
microfilariae
+ ++ + +
Macrophage responses to adult
worms
+ ++ ++ ++
Score: + = mild; ++ = moderate; +++ = severe
https://doi.org/10.1371/journal.pntd.0005576.t003
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treatment with a single dose of ivermectin resulted in mild hepatotoxicity. Elevations in SGPT
and SGOT in blood are increased in conditions in which cells are damaged or dead. It is also
important to note that the elevations in serum liver enzymes can also be secondary to enzyme
induction without hepatic pathology [34]. The elevations of creatinine post-treatment in con-
trol animals was not surprising because during the course of infection after inoculation of mfs
into these animals, its’ levels were already high. This could probably be related to kidney dys-
function [35] as a malfunction in glomerular filtration results in the retention of substances
including urea and creatinine. Generally, creatinine levels dropped in all animals that took
ivermectin alone, or ivermectin together with other treatments. This decrease is probably due
to the fact that the kidneys were more efficient in excreting the compound. The elevated serum
glucose level observed may have resulted from increased mobilization of glucose for metabo-
lism or may be due to reduced glucose uptake into cells caused by ivermectin [36] or a possible
modulation of the capacity of the renal tubule by the drug to reabsorb glucose actively from
the blood [36]. The decrease in potassium levels in untreated animals could probably be due to
a reduced intake in their diet [37] or a decreased sensitivity of the nephron to aldosterone and
other mineralocorticoids responsible for reabsorption and retention of electrolytes, respec-
tively. However, the drop in potassium levels in animals administered ivermectin and predni-
sone is probably due to the fact that prednisone is known to cause more urination as more
blood moves to the kidneys. It is probable that as more urine is sent out, more potassium ions
are also lost along with it from the body in these animals or reduced intake in their diet [37].
The changes in calcium ions pre and post treatment could probably be related to variations in
diet intake of this mineral [38].
Generally, all animals administered ivermectin became withdrawn 48 hours following treat-
ment. This observation is in line with the results of earlier studies [12, 13] which revealed that
symptoms appeared within two days of ivermectin treatment in patients who were previously
healthy. This withdrawal attitude could be due to stress that developed due to loss of coordina-
tion, reduced alertness that can progress to stupor or coma. A withdrawn attitude is a neuro-
logical manifestation that is related to blockage and reduced blood flow supplying nutrients
and oxygen to the cells that could be due to the destruction or death of mf in the brain and
other tissues. A possible scenario for the pathogenesis of the animal that died 5 hours after
ivermectin treatment could be that at the time of ivermectin treatment, this animal harbored a
Loa mf load (124,700mf/mL) greatly exceeding the threshold associated with the risk of post-
ivermectin Loa encephalopathy. The initial L. loa microfilarial load has been demonstrated to
be the main risk factor for the development of serious reactions and an association has been
found to exist between L. loa load and the occurrence of marked or serious reactions has been
found to be significant above 8,000mf/mL with the association being close and stable [12,13].
In all animals treated with ivermectin, there was the development of body rashes and itches
in otherwise healthy animals just one day after treatment. The development of rashes could
probably be due to an enhancement in the production of many more leukocytes (such as
eosinophils and neutrophils) to reduce the severity of Mazzotti reaction and to fight the infec-
tion in general; these cells being the hallmarks of acute inflammation. The presence of haemor-
rhages with evidence of L. loa mf seen in the brain, eyes and other organs of treated animals
could probably be due to the fact that ivermectin results in rapid killing of Loa mf in these tis-
sues. The obstruction of blood capillaries by these dead worms in these organs could lead to an
ischemic reaction, increased pressure within the capillaries, rupture of the affected vessel(s)
and haemorrhagic suffusion. This observed vasculopathy with evidence of L. loa as a likely eti-
ology in the brain tissue therefore confirms the definite case of Loa encephalopathy as put
forth by the group of independent experts who consulted for MDP immediately after the first
cases of SAEs were noticed in the 1990s. Lymphadenopathy was present in all baboons that
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received ivermectin. Enlarged lymph nodes generally result from the accumulation of leuco-
cytes within the lymph glands. Ivermectin, has been shown to cause an increase in the total
white blood cell counts, number of eosinophils, and neutrophils [10].
Our results suggest that the pathogenesis of Loa encephalopathy is as a result of the death of
mf in the blood vessels in the brain. This event causing inflammation to set in with the activa-
tion of the fibrin pathway with fibrin clots being deposited and these blocking the blood vessels
in the brain and other tissues. This deposition of fibrin clots damages the walls of these blood
vessels as a result of the release of inflammatory cytokines and these overall pathologic pro-
cesses affecting the local tissues through tissue anoxia and other detrimental changes that even-
tually result in the permanent damage and in some cases the death of the host (Fig 11).
For the first time, this study has provided information on the tissues and body fluids where
mf could be found after ivermectin treatment of Loa heavily infected individuals. Generally,
organs that normally receive large amounts of blood were noticed to be harbouring many
more microfilariae than those less irrigated. Given that Loa loa is a blood dwelling filarial
Fig 11. Potential pathogenesis of Loa encephalopathy following the ivermectin treatment of Loa hyper-microfilaraemic
individuals.
https://doi.org/10.1371/journal.pntd.0005576.g011
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worm, its presence in these highly irrigated organs is to be expected. It is not known as to why
aspirin and prednisone lead to a decrease or an increase in the number of tissue sections. The
presence of microfilariae in other body fluids (peritoneal and pericardial) collected at autopsy
could probably be due to the fact ivermectin treatment induces the Loa microfilariae to flee
from the blood circulation. This is an important finding which indicates that in those humans
who suffer from SAEs, the serious events noticed could be due to breathing difficulties due to
the accumulation of fluid in the lungs or complications such as ascites which might cause diffi-
culties in compressing the diaphragm leading to breathing difficulties. The discovery of the
presence of these effusions could serve as an important step in managing the SAEs clinically as
these fluids could be drained and an intravenous infusion administered to these patients to
balance fluid and electrolytes.
The primary lesions seen in the untreated infected animals were peri-portal accumulation
of lymphocytes; as present in all of the animals. It is likely that in addition to the spleen, this
organ and the peri-portal region is a common location for the degeneration of microfilariae. It
is also possible that this occurs as a result of the initial removal of the spleen as part of the
infection process, and the liver has become the default site for microfilarial destruction. It is
clear that a major pathogenic event following ivermectin is a vasculopathy associated with the
death and degeneration, with a cellular response, and all of this taking place intravascularly.
Although there is on occasion clear damage and the resulting haemorrhaging of vessels, it is
more likely that this vascular blockage results in acute parenchymal damage or dysfunction in
the brain that results in the clinical condition.
Generally, in this study we found out that animals administered aspirin showed milder
symptoms compared to those that received prednisone. Aspirin is part of a group of medica-
tions called non-steroidal anti-inflammatory drugs (NSAIDs), but differs from most other
NSAIDs in the mechanism of action. It produces lipoxins, most of which are anti-inflamma-
tory [39]. It is probable that the lipoxins produced by this drug aid in alleviating the symptoms
observed in animals after treatment with ivermectin. The finding that prednisone aggravates
the clinical manifestations observed corroborates the assertions made by Boussinesq et al. [40]
that corticosteroids do not have any beneficial effect on the course of these clinical manifesta-
tions because they might lead to iatrogenic lethal complications.
The influx of significant number of eosinophils into the tissues shortly after ivermectin
treatment is likely to be a significant contributor to the pathogenesis of the condition or at
least the clinical presentation. Release of toxic mediators from the activation of eosinophils
would probably be an important factor in the pathogenesis of this condition.
Conclusions
The findings presented from this study have revealed that the ivermectin treatment of Loa
hypermicrofilaraemic animals induces a drastic reduction in mf numbers with an 80%
decrease observed in some animals. Hb was the only observed parameter that recorded a slight
significant value pre and post treatment. Clinical manifestations observed after treatment are
similar to what have been observed in humans such as rashes, itching, haemorrhagic conjunc-
tiva, increased temperature, increased pulse and respiratory rates, diarrhoea, lymph node
enlargement, pinkish ears, swollen face and restlessness. Macroscopic changes noticed were
primarily those of a vasculo-pathologic nature (e.g. haemorrhages) seen in all groups given
ivermectin, occurring at various levels, except in the untreated. Microscopically, the major cel-
lular changes seen, and present in all the ivermectin treated animals, were: the presence of
microfilariae of varying degrees of degeneration associated with either fibrin deposition, endo-
thelial alteration (cellular swelling) including damage to the integrity of the blood vessel and
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the presence of extravascular erythrocytes (haemorrhage), the increased presence of eosinophil
leucocytes and other chronic inflammatory types in certain tissues and organs, sometimes in
large numbers and local evidence of microfilarial death. Highly vascularised organs like the
brain, heart, lungs, and kidneys were observed to have more microfilariae in tissue sections.
The number of mf seen in the brain and kidneys of animals administered IVM only, tripled
that of control animals. Co-administration of IVM + PSE caused an increase in mf in the brain
and kidneys while the reverse was noticed with the co-administration of IVM+ASA. The iver-
mectin treatment of Loa hyper-microfilaraemic baboons has revealed that the formation of
fibrin clots and the presence of pleural and peritoneal effusions could probably be related to
the development of the pathological conditions noticed in those Loa hypermicrofilaraemic
humans who were administered ivermectin.
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